% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hemminki:170446,
      author       = {K. Hemminki$^*$ and A. Försti$^*$ and M. Hansson},
      title        = {{I}ncidence, mortality and survival in multiple myeloma
                      compared to other hematopoietic neoplasms in {S}weden up to
                      year 2016.},
      journal      = {Scientific reports},
      volume       = {11},
      number       = {1},
      issn         = {2045-2322},
      address      = {[London]},
      publisher    = {Macmillan Publishers Limited, part of Springer Nature},
      reportid     = {DKFZ-2021-01939},
      pages        = {17272},
      year         = {2021},
      abstract     = {Survival in multiple myeloma (MM) has developed favorably
                      over the past decades for reasons that have been ascribed to
                      new medications and treatment. However, development of
                      survival over a long period and comparison to other
                      hematopoietic neoplasms (HN) is less well known. Here we
                      used Swedish cancer data from the Nordcan database, spanning
                      a 50-year period from 1967 to 2016, and analyzed 1- and
                      5-year survival data. As a novel type of analysis we
                      calculate the difference in survival between year 1 and 5
                      which indicates how well survival was maintained in the
                      4-year period following year 1 after diagnosis. The relative
                      1- and 5- year survival increased constantly; the 5-year
                      survival graph for women was almost linear. The difference
                      between 1- and 5-year survival revealed that the 5-year
                      survival gain was entirely due to the improvement in 1-year
                      survival, except for the last period. Survival improvement
                      in all HNs exceeded that in MM. The linear 5-year survival
                      increase for female MM patients suggests a contribution by
                      many small improvements in the first year care rather than
                      single major events. The future challenges are to push the
                      gains past year 1 and to extend them to old patients.},
      cin          = {B062 / HD01},
      ddc          = {600},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34446811},
      doi          = {10.1038/s41598-021-96804-8},
      url          = {https://inrepo02.dkfz.de/record/170446},
}